Cevian's continued accumulation at a $12.8B market cap suggests it sees significant upside from operational improvements or a strategic sale. Traders should monitor for a potential 13D amendment detailing Cevian's specific demands, which could catalyze a re-rating. The stock may see increased volatility as the activist builds its position.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 12 $29.84entry
- T+1 · 3mo ago +0.90%α +0.21% · $30.11
- T+5 · 3mo ago −1.78%α −1.33% · $29.31
- T+20 · 2mo ago −7.44%α −5.54% · $27.62
- T+60 · 12d ago +7.27%α +12.38% · $32.01
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Activist investor Cevian Capital increased its stake in Smith & Nephew to 14.21% from 14.01%, accumulating shares through its Master Fund and Co-Investment vehicle. This is a continuation of Cevian's existing activist campaign, signaling growing conviction and potential pressure for operational or strategic changes at the orthopedic device maker. The incremental accumulation, while not crossing a new threshold, reinforces the activist's presence and could increase the likelihood of a breakup, divestiture, or management shakeup.
Key Facts
- Cevian Capital II GP Limited increased its aggregate holding in Smith & Nephew to 14.214414% from 14.010786%.
- The increase was driven by a rise in the Cevian Capital II Master Fund L.P. stake to 13.014856% (from 12.815710%).
- Cevian Capital II Co-Investment - Series P L.P. holds 1.199558% (up from 1.195075%).
- The total number of voting rights held is 119,179,419 shares.
- The notification date is August 11, 2026, for a threshold crossing on August 7, 2026.
Financial Impact
Cevian now controls 14.21% of SNN, representing approximately $1.8B of the $12.8B market cap.
Risk Factors
- Cevian may not achieve its desired changes, leading to a prolonged and costly campaign.
- The incremental increase is small (0.2%) and may not immediately force management action.
- Smith & Nephew's underlying business fundamentals (recent revenue/earnings trends) could deteriorate, offsetting any activist premium.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-007490 |
| Document: 0001654954-26-007490-index-headers.html | 0001654954-26-007490 |
| Document: 0001654954-26-007490-index.html | 0001654954-26-007490 |
| Document: 0001654954-26-007490.txt | 0001654954-26-007490 |
Track record
42 reports on SNN
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +8.02% at T+20 after the Jun 30, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 1/10 Entry $31.00 Now $30.97 −0.10% settles Nov 19
- Nov 4, 202612d ago 6-K Bearish 6/10 No price data
- Nov 4, 202612d ago 6-K Bearish 6/10 Entry $32.46 to $31.04 Now $30.97 +4.59% ▲ +4.37% +3.46% vs SPY
- Nov 2, 202614d ago 6-K Neutral 4/10 Entry $30.24 to $31.05 Now $30.97 +2.41% ▲ +2.68% +2.60% vs SPY
- Oct 22, 202625d ago 6-K Neutral 2/10 Entry $30.88 to $30.22 Now $30.97 +0.29% ▼ −2.14% −2.84% vs SPY
- Oct 8, 20265w ago 6-K Neutral 2/10 Entry $26.96 to $29.09 Now $30.97 +14.87% ▲ +7.90% +8.18% vs SPY
- Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
- Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
- Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
- Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers